Table 2.
Baseline characteristics
| Variable | No. (%), N = 46 |
|---|---|
| Age, y (mean ± standard deviation) | 38.6 ± 10.7 |
| ≤40 | 23 (50) |
| >40 | 23 (50) |
| Disease state | |
| New diagnosis | 35 (76.1) |
| Refractory or relapsed | 11 (23.9) |
| Gender | |
| Female | 10 (21.7) |
| Male | 36 (78.3) |
| Primary site at diagnosis | |
| Nonupper respiratory tract | 11 (23.9) |
| Upper respiratory tract | 35 (76.1) |
| Stage | |
| I | 11 (23.9) |
| II | 15 (32.6) |
| III or IV | 20 (43.5) |
| B symptoms | 32 (69.6) |
| Elevated LDL cholesterol | 25 (54.3) |
| Elevated ferroprotein | 32 (69.6) |
| Elevated β‐microglobulin | 22 (47.8) |
| Cells positive for Ki‐67 expression, %a | |
| ≤60 | 22 (52.4) |
| >60 | 20 (47.6) |
| ECOG performance status | |
| 0 | 21 (45.6) |
| ≥1 | 25 (54.4) |
| International prognostic index | |
| 0 | 11 (23.9) |
| 1 | 21 (45.7) |
| ≥2 | 14 (30.4) |
| Prior treatment | |
| None | 38 (82.6) |
| Chemotherapyb | 8 (17.4) |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; LDL, low‐density lipoprotein.
a
Four patients had no data on the percentage of cells positive for Ki‐67 expression.
Prior treatment included cyclophosphamide‐hydroxydaunorubicin‐vincristine‐prednisone (CHOP) in 2 cases (1 patient received both CHOP and CHOP‐etoposide), CHOP‐etoposide in 2 cases, and CHOP‐L‐asparaginase in 5 cases. No patients received radiotherapy in prior treatment.